| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
20,950 |
6,658 |
$566K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
6,618 |
5,000 |
$268K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
18,494 |
5,736 |
$116K |
| 87481 |
|
5,855 |
4,448 |
$85K |
| 87640 |
|
6,748 |
5,027 |
$22K |
| 87500 |
|
5,826 |
4,421 |
$21K |
| 87653 |
|
5,869 |
4,452 |
$21K |
| 87641 |
|
3,745 |
2,780 |
$13K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
2,075 |
1,531 |
$6K |
| 87631 |
|
661 |
491 |
$5K |
| 87471 |
|
1,489 |
1,111 |
$5K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
864 |
672 |
$3K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
868 |
674 |
$3K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
866 |
673 |
$3K |
| 87563 |
|
858 |
671 |
$3K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
82 |
61 |
$2K |
| 87541 |
|
516 |
376 |
$2K |
| 87581 |
|
516 |
376 |
$2K |
| 87486 |
|
638 |
476 |
$2K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
40 |
36 |
$479.00 |